200 related articles for article (PubMed ID: 16321730)
1. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.
Correll CU; Penzner JB; Parikh UH; Mughal T; Javed T; Carbon M; Malhotra AK
Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):177-206. PubMed ID: 16321730
[TBL] [Abstract][Full Text] [Related]
2. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents.
Correll CU
J Clin Psychiatry; 2008; 69 Suppl 4():26-36. PubMed ID: 18533766
[TBL] [Abstract][Full Text] [Related]
3. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients.
Correll CU
Int Rev Psychiatry; 2008 Apr; 20(2):195-201. PubMed ID: 18386212
[TBL] [Abstract][Full Text] [Related]
4. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses.
McConville BJ; Sorter MT
J Clin Psychiatry; 2004; 65 Suppl 6():20-9. PubMed ID: 15104523
[TBL] [Abstract][Full Text] [Related]
5. Use of antipsychotics in children and adolescents.
Findling RL; Steiner H; Weller EB
J Clin Psychiatry; 2005; 66 Suppl 7():29-40. PubMed ID: 16124839
[TBL] [Abstract][Full Text] [Related]
6. Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists.
Walter G; DeLaroche A; Soh N; Hunt G; Cleary M; Malhi G; Lambert T; Correll C; Rey J
Australas Psychiatry; 2008 Aug; 16(4):253-62. PubMed ID: 18608172
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic drug toxicology in children.
Caccia S; Clavenna A; Bonati M
Expert Opin Drug Metab Toxicol; 2011 May; 7(5):591-608. PubMed ID: 21401439
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns.
Vitiello B; Correll C; van Zwieten-Boot B; Zuddas A; Parellada M; Arango C
Eur Neuropsychopharmacol; 2009 Sep; 19(9):629-35. PubMed ID: 19467582
[TBL] [Abstract][Full Text] [Related]
9. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome.
Shirzadi AA; Ghaemi SN
Harv Rev Psychiatry; 2006; 14(3):152-64. PubMed ID: 16787887
[TBL] [Abstract][Full Text] [Related]
10. Adverse events in children and adolescents treated with antipsychotic medications.
Jerrell JM; McIntyre RS
Hum Psychopharmacol; 2008 Jun; 23(4):283-90. PubMed ID: 18302312
[TBL] [Abstract][Full Text] [Related]
11. Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia.
Correll CU
J Clin Psychiatry; 2011 Jan; 72(1):e01. PubMed ID: 21272508
[TBL] [Abstract][Full Text] [Related]
12. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
13. Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use.
de Leon J
J Clin Psychopharmacol; 2008 Apr; 28(2):125-31. PubMed ID: 18344721
[No Abstract] [Full Text] [Related]
14. Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists.
Pisano S; Catone G; Veltri S; Lanzara V; Pozzi M; Clementi E; Iuliano R; Riccio MP; Radice S; Molteni M; Capuano A; Gritti A; Coppola G; Milone A; Bravaccio C; Masi G
Ital J Pediatr; 2016 May; 42(1):51. PubMed ID: 27209326
[TBL] [Abstract][Full Text] [Related]
15. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.
Morrato EH; Cuffel B; Newcomer JW; Lombardo I; Kamat S; Barron J
J Clin Psychopharmacol; 2009 Feb; 29(1):26-32. PubMed ID: 19142103
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel program to facilitate monitoring physical health and adverse effects in children and adolescents prescribed antipsychotic medication.
Ellis D; Shirzadi K; Grzeskowiak L; Angley M
Australas Psychiatry; 2008 Oct; 16(5):368-9. PubMed ID: 18781460
[No Abstract] [Full Text] [Related]
17. [Risperidone use in child and adolescent psychiatric patients].
Chevreuil C; Reymann JM; Frémaux T; Polard E; Séveno T; Bentué-Ferrer D
Therapie; 2008; 63(5):359-75. PubMed ID: 19154706
[TBL] [Abstract][Full Text] [Related]
18. Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
Leucht S; Kissling W; Davis JM
Psychol Med; 2009 Oct; 39(10):1591-602. PubMed ID: 19335931
[TBL] [Abstract][Full Text] [Related]
19. Treatment of bipolar disorders and metabolic syndrome: implications for primary care.
Bell PF; McKenna JP; Roscoe BM
Postgrad Med; 2009 Sep; 121(5):140-4. PubMed ID: 19820282
[TBL] [Abstract][Full Text] [Related]
20. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
McIntyre RS; Jerrell JM
Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
